X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Formulating infliximab as an oral capsule – which must survive the digestive system's harsh environment and reach the colon intact – is transformational.
Lead Product(s): Infliximab
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Intract Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 18, 2022
Details:
French biotech firm Biophytis will assess its Sarconeos (BIO101) drug as a treatment for respiratory failure caused by Covid-19 after partnering with contract research organisation (CRO) SGS.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biophytis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 08, 2020
Details:
This pivotal, international clinical trial will be conducted in two parts, the first of which has the objective to assess treatment safety and provide an indication of activity of Sarconeos, in 50 hospitalized COVID-19 patients suffering from acute respiratory deficiency.
Lead Product(s): 20-Hydroxyecdysone
Therapeutic Area: Infections and Infectious Diseases Product Name: BIO101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Biophytis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
